Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
Journal
British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635
Informations de publication
Date de publication:
04 Mar 2024
04 Mar 2024
Historique:
received:
23
09
2023
accepted:
14
02
2024
revised:
12
02
2024
medline:
5
3
2024
pubmed:
5
3
2024
entrez:
4
3
2024
Statut:
aheadofprint
Résumé
Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% of uterine cancer deaths, which is attributed to tumor aggressiveness and limited effective treatment. Galectin 3 (Gal3) has been implicated in promoting aggressive features in some malignancies. However, Gal3's role in promoting USC pathology is lacking. We explored the relationship between LGALS3 levels and prognosis in USC patients using TCGA database, and examined the association between Gal3 levels in primary USC tumors and clinical-pathological features. CRISPR/Cas9-mediated Gal3-knockout (KO) and GB1107, inhibitor of Gal3, were employed to evaluate Gal3's impact on cell function. TCGA analysis revealed a worse prognosis for USC patients with high LGALS3. Patients with no-to-low Gal3 expression in primary tumors exhibited reduced clinical-pathological tumor progression. Gal3-KO and GB1107 reduced cell proliferation, stemness, adhesion, migration, and or invasion properties of USC lines. Furthermore, Gal3-positive conditioned media (CM) stimulated vascular tubal formation and branching and transition of fibroblast to cancer-associated fibroblast compared to Gal3-negative CM. Xenograft models emphasized the significance of Gal3 loss with fewer and smaller tumors compared to controls. Moreover, GB1107 impeded the growth of USC patient-derived organoids. These findings suggest inhibiting Gal3 may benefit USC patients.
Sections du résumé
BACKGROUND
BACKGROUND
Uterine serous cancer (USC) comprises around 10% of all uterine cancers. However, USC accounts for approximately 40% of uterine cancer deaths, which is attributed to tumor aggressiveness and limited effective treatment. Galectin 3 (Gal3) has been implicated in promoting aggressive features in some malignancies. However, Gal3's role in promoting USC pathology is lacking.
METHODS
METHODS
We explored the relationship between LGALS3 levels and prognosis in USC patients using TCGA database, and examined the association between Gal3 levels in primary USC tumors and clinical-pathological features. CRISPR/Cas9-mediated Gal3-knockout (KO) and GB1107, inhibitor of Gal3, were employed to evaluate Gal3's impact on cell function.
RESULTS
RESULTS
TCGA analysis revealed a worse prognosis for USC patients with high LGALS3. Patients with no-to-low Gal3 expression in primary tumors exhibited reduced clinical-pathological tumor progression. Gal3-KO and GB1107 reduced cell proliferation, stemness, adhesion, migration, and or invasion properties of USC lines. Furthermore, Gal3-positive conditioned media (CM) stimulated vascular tubal formation and branching and transition of fibroblast to cancer-associated fibroblast compared to Gal3-negative CM. Xenograft models emphasized the significance of Gal3 loss with fewer and smaller tumors compared to controls. Moreover, GB1107 impeded the growth of USC patient-derived organoids.
CONCLUSION
CONCLUSIONS
These findings suggest inhibiting Gal3 may benefit USC patients.
Identifiants
pubmed: 38438589
doi: 10.1038/s41416-024-02621-x
pii: 10.1038/s41416-024-02621-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Uehara Memorial Foundation
ID : NA
Informations de copyright
© 2024. The Author(s).
Références
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.
pubmed: 36633525
doi: 10.3322/caac.21763
Lee EK, Fader AN, Santin AD, Liu JF. Uterine serous carcinoma: Molecular features, clinical management, and new and future therapies. Gynecol Oncol. 2021;160:322–32.
pubmed: 33160694
doi: 10.1016/j.ygyno.2020.10.017
Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642–6.
pubmed: 16495918
pmcid: 2361201
doi: 10.1038/sj.bjc.6603012
Sherman ME, Devesa SS. Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus. Cancer. 2003;98:176–86.
pubmed: 12833470
doi: 10.1002/cncr.11484
Corey L, Cote ML, Ruterbusch JJ, Vezina A, Winer I. Disparities in adjuvant treatment of high-grade endometrial cancer in the Medicare population. Am J Obstet Gynecol. 2022;226:541.e1–e13.
pubmed: 34736911
doi: 10.1016/j.ajog.2021.10.031
Bregar AJ, Alejandro Rauh-Hain J, Spencer R, Clemmer JT, Schorge JO, Rice LW, et al. Disparities in receipt of care for high-grade endometrial cancer: A National Cancer Data Base analysis. Gynecol Oncol. 2017;145:114–21.
pubmed: 28159409
doi: 10.1016/j.ygyno.2017.01.024
Sponholtz TR, Palmer JR, Rosenberg L, Chen C, Chen Y, Clarke MA, et al. Risk factors for endometrial cancer in Black women. Cancer Causes Control. 2023;34:421–30.
pubmed: 36418803
doi: 10.1007/s10552-022-01653-z
Fader AN, Drake RD, O’Malley DM, Gibbons HE, Huh WK, Havrilesky LJ, et al. Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer. 2009;115:2119–27.
pubmed: 19306417
doi: 10.1002/cncr.24247
Li CH, Chang YC, Chan MH, Yang YF, Liang SM, Hsiao M. Galectins in cancer and the microenvironment: functional roles, therapeutic developments, and perspectives. Biomedicines. 2021;9:1159.
pubmed: 34572346
pmcid: 8465754
doi: 10.3390/biomedicines9091159
Levi G, Teichberg VI. Isolation and physicochemical characterization of electrolectin, a beta-D-galactoside binding lectin from the electric organ of Electrophorus electricus. J Biol Chem. 1981;256:5735–40.
pubmed: 7240169
doi: 10.1016/S0021-9258(19)69268-9
Shimada C, Xu R, Al-Alem L, Stasenko M, Spriggs DR, Rueda BR. Galectins and ovarian cancer. Cancers. 2020;12:1421.
pubmed: 32486344
pmcid: 7352943
doi: 10.3390/cancers12061421
Farhad M, Rolig AS, Redmond WL. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology. 2018;7:e1434467.
pubmed: 29872573
pmcid: 5980349
doi: 10.1080/2162402X.2018.1434467
Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 2000;156:899–909.
pubmed: 10702407
pmcid: 1876842
doi: 10.1016/S0002-9440(10)64959-0
Wang D, You D, Li L. Galectin-3 regulates chemotherapy sensitivity in epithelial ovarian carcinoma via regulating mitochondrial function. J Toxicol Sci. 2019;44:47–56.
pubmed: 30626779
doi: 10.2131/jts.44.47
Stasenko M, Smith E, Yeku O, Park KJ, Laster I, Lee K, et al. Targeting galectin-3 with a high-affinity antibody for inhibition of high-grade serous ovarian cancer and other MUC16/CA-125-expressing malignancies. Sci Rep. 2021;11:3718.
pubmed: 33580170
pmcid: 7881041
doi: 10.1038/s41598-021-82686-3
Al-Maghrabi J, Abdelrahman AS, Ghabrah T, Butt NS, Al-Maghrabi B, Khabaz MN. Immunohistochemical expression of galectin-3 is significantly associated with grade, stage and differentiation of endometrial carcinomas. Pathol Res Pr. 2017;213:348–52.
doi: 10.1016/j.prp.2017.01.012
Lambropoulou M, Deftereou TE, Kynigopoulos S, Patsias A, Anagnostopoulos C, Alexiadis G, et al. Co-expression of galectin-3 and CRIP-1 in endometrial cancer: prognostic value and patient survival. Med Oncol. 2016;33:8.
pubmed: 26708131
doi: 10.1007/s12032-015-0723-7
Brustmann H, Riss D, Naudé S. Galectin-3 expression in normal, hyperplastic, and neoplastic endometrial tissues. Pathol Res Pr. 2003;199:151–8.
doi: 10.1078/0344-0338-00368
Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, et al. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts. Clin Cancer Res. 2014;20:6517–28.
pubmed: 25294905
pmcid: 4268047
doi: 10.1158/1078-0432.CCR-14-1647
Sumana BS, Shashidhar S, Shivarudrappa AS. Galectin-3 immunohistochemical expression in thyroid neoplasms. J Clin Diagn Res. 2015;9:Ec07–11.
pubmed: 26673516
pmcid: 4668414
English DP, Bellone S, Cocco E, Bortolomai I, Pecorelli S, Lopez S, et al. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2). Am J Obstet Gynecol. 2013;209:465.e1–9.
pubmed: 23891627
doi: 10.1016/j.ajog.2013.07.020
English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, et al. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol. 2013;131:753–8.
pubmed: 24012800
doi: 10.1016/j.ygyno.2013.08.033
Garrett LA, Growdon WB, Rueda BR, Foster R. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer. J Ovarian Res. 2016;9:58.
pubmed: 27633667
pmcid: 5025559
doi: 10.1186/s13048-016-0267-2
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8:1404–21.
pubmed: 30213835
pmcid: 6365285
doi: 10.1158/2159-8290.CD-18-0474
Sanjana NE, Shalem O, Zhang F. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods. 2014;11:783–4.
pubmed: 25075903
pmcid: 4486245
doi: 10.1038/nmeth.3047
Rao TD, Fernández-Tejada A, Axelrod A, Rosales N, Yan X, Thapi S, et al. Antibodies against specific MUC16 Glycosylation sites inhibit ovarian cancer growth. ACS Chem Biol. 2017;12:2085–96.
pubmed: 28617578
pmcid: 5603915
doi: 10.1021/acschembio.7b00305
van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237–45.
pubmed: 21516412
doi: 10.1007/978-1-61779-080-5_20
Fraser C, Ryan J, Sarosiek K. BH3 profiling: A functional assay to measure apoptotic priming and dependencies. Methods Mol Biol. 2019;1877:61–76.
pubmed: 30535998
pmcid: 7325165
doi: 10.1007/978-1-4939-8861-7_4
Starbuck K, Al-Alem L, Eavarone DA, Hernandez SF, Bellio C, Prendergast JM, et al. Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau. Oncotarget. 2018;9:23289–305.
pubmed: 29796189
pmcid: 5955411
doi: 10.18632/oncotarget.25289
Cardozo ER, Foster R, Karmon AE, Lee AE, Gatune LW, Rueda BR, et al. MicroRNA 21a-5p overexpression impacts mediators of extracellular matrix formation in uterine leiomyoma. Reprod Biol Endocrinol. 2018;16:46.
pubmed: 29747655
pmcid: 5946472
doi: 10.1186/s12958-018-0364-8
Rao TD, Tian H, Ma X, Yan X, Thapi S, Schultz N, et al. Expression of the Carboxy-Terminal portion of MUC16/CA125 induces transformation and tumor invasion. PLoS One. 2015;10:e0126633.
pubmed: 25965947
pmcid: 4429113
doi: 10.1371/journal.pone.0126633
Toboni MD, Lomonosova E, Bruce SF, Tankou JI, Mullen MM, Schab A, et al. Inhibition of AXL and VEGF-A has improved therapeutic efficacy in uterine serous cancer. Cancers. 2021;13:5877.
pubmed: 34884986
pmcid: 8656641
doi: 10.3390/cancers13235877
Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. Gynecol Oncol. 2016;141:570–9.
pubmed: 27017985
doi: 10.1016/j.ygyno.2016.03.027
Piyush T, Chacko AR, Sindrewicz P, Hilkens J, Rhodes JM, Yu LG. Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells. Cell Death Differ. 2017;24:1937–47.
pubmed: 28731466
pmcid: 5635220
doi: 10.1038/cdd.2017.119
Groeneweg JW, DiGloria CM, Yuan J, Richardson WS, Growdon WB, Sathyanarayanan S, et al. Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth. Front Oncol. 2014;4:171.
pubmed: 25072022
pmcid: 4083224
doi: 10.3389/fonc.2014.00171
McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci USA. 2012;109:E2939–48.
pubmed: 23019585
pmcid: 3491453
doi: 10.1073/pnas.1206400109
Allam H, Johnson BP, Zhang M, Lu Z, Cannon MJ, Abbott KL. The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer. J Biol Chem. 2017;292:16351–9.
pubmed: 28842505
pmcid: 5625063
doi: 10.1074/jbc.M117.783936
Lau KS, Partridge EA, Grigorian A, Silvescu CI, Reinhold VN, Demetriou M, et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell. 2007;129:123–34.
pubmed: 17418791
doi: 10.1016/j.cell.2007.01.049
Fukumori T, Oka N, Takenaka Y, Nangia-Makker P, Elsamman E, Kasai T, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res. 2006;66:3114–9.
pubmed: 16540661
doi: 10.1158/0008-5472.CAN-05-3750
Fukumori T, Kanayama HO, Raz A. The role of galectin-3 in cancer drug resistance. Drug Resist Updat. 2007;10:101–8.
pubmed: 17544840
pmcid: 3626271
doi: 10.1016/j.drup.2007.04.001
Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011;334:1129–33.
pubmed: 22033517
doi: 10.1126/science.1206727
Fraser CS, Spetz JKE, Qin X, Presser A, Choiniere J, Li C, et al. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. Nat Commun. 2022;13:5789.
pubmed: 36184661
pmcid: 9527241
doi: 10.1038/s41467-022-33461-z
DeRoo EP, Wrobleski SK, Shea EM, Al-Khalil RK, Hawley AE, Henke PK, et al. The role of galectin-3 and galectin-3-binding protein in venous thrombosis. Blood. 2015;125:1813–21.
pubmed: 25428218
pmcid: 4357586
doi: 10.1182/blood-2014-04-569939
Al-Alem LF, Pandya UM, Baker AT, Bellio C, Zarrella BD, Clark J, et al. Ovarian cancer stem cells: What progress have we made? Int J Biochem Cell Biol. 2019;107:92–103.
pubmed: 30572025
doi: 10.1016/j.biocel.2018.12.010
Giannone G, Attademo L, Scotto G, Genta S, Ghisoni E, Tuninetti V, et al. Endometrial cancer stem cells: role, characterization and therapeutic implications. Cancers. 2019;11:1820.
pubmed: 31752447
pmcid: 6896186
doi: 10.3390/cancers11111820
Grazier JJ, Sylvester PW Role of Galectins in Metastatic Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer. Brisbane (AU): Exon Publications; (2022).
Hayashi Y, Jia W, Kidoya H, Muramatsu F, Tsukada Y, Takakura N. Galectin-3 inhibits cancer metastasis by negatively regulating Integrin β3 Expression. Am J Pathol. 2019;189:900–10.
pubmed: 30653955
doi: 10.1016/j.ajpath.2018.12.005
Nithiananthan S, Crawford A, Knock JC, Lambert DW, Whawell SA. Physiological fluid flow moderates fibroblast responses to TGF-beta1. J Cell Biochem. 2017;118:878–90.
pubmed: 27748539
doi: 10.1002/jcb.25767
Zainal Abidin SAI, Paterson IC, Hunt S, Lambert DW, Higginbotham S, Pink RC. Myofibroblast transdifferentiation is associated with changes in cellular and extracellular vesicle miRNA abundance. PLoS One. 2021;16:e0256812.
pubmed: 34762649
pmcid: 8584782
doi: 10.1371/journal.pone.0256812
Ahmed H, AlSadek DM. Galectin-3 as a potential target to prevent cancer metastasis. Clin Med Insights Oncol. 2015;9:113–21.
pubmed: 26640395
pmcid: 4662425
doi: 10.4137/CMO.S29462
Chen Y, Xu J, Pan W, Xu X, Ma X, Chu Y, et al. Galectin-3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2-positive breast cancer cells. Thorac Cancer. 2022;13:1961–73.
pubmed: 35599381
pmcid: 9250839
doi: 10.1111/1759-7714.14474
Pang Y, Maxwell E, Sindrewicz-Goral P, Shapanis A, Li S, Morgan M, et al. Galectin-3 is a natural binding ligand of MCAM (CD146, MUC18) in melanoma cells and their interaction promotes melanoma progression. Biomolecules. 2022;12:1451.
pubmed: 36291660
pmcid: 9599063
doi: 10.3390/biom12101451
Kobayashi T, Shimura T, Yajima T, Kubo N, Araki K, Tsutsumi S, et al. Transient gene silencing of galectin-3 suppresses pancreatic cancer cell migration and invasion through degradation of β-catenin. Int J Cancer. 2011;129:2775–86.
pubmed: 21448903
doi: 10.1002/ijc.25946
Kuo HY, Hsu HT, Chen YC, Chang YW, Liu FT, Wu CW. Galectin-3 modulates the EGFR signalling-mediated regulation of Sox2 expression via c-Myc in lung cancer. Glycobiology. 2016;26:155–65.
pubmed: 26447186
doi: 10.1093/glycob/cwv088
Chung LY, Tang SJ, Wu YC, Sun GH, Liu HY, Sun KH. Galectin-3 augments tumor initiating property and tumorigenicity of lung cancer through interaction with β-catenin. Oncotarget. 2015;6:4936–52.
pubmed: 25669973
doi: 10.18632/oncotarget.3210
Ilmer M, Mazurek N, Byrd JC, Ramirez K, Hafley M, Alt E, et al. Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics. Cell Death Dis. 2016;7:e2337.
pubmed: 27512958
pmcid: 5108324
doi: 10.1038/cddis.2016.239
Huang CS, Tang SJ, Lee MH, Chang Wang CC, Sun GH, Sun KH. Galectin-3 promotes CXCR2 to augment the stem-like property of renal cell carcinoma. J Cell Mol Med. 2018;22:5909–18.
pubmed: 30246456
pmcid: 6237593
doi: 10.1111/jcmm.13860
Kang HG, Kim DH, Kim SJ, Cho Y, Jung J, Jang W, et al. Galectin-3 supports stemness in ovarian cancer stem cells by activation of the Notch1 intracellular domain. Oncotarget. 2016;7:68229–41.
pubmed: 27626163
pmcid: 5356551
doi: 10.18632/oncotarget.11920
Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol. 2002;15:1032–7.
pubmed: 12379748
doi: 10.1097/01.MP.0000028573.34289.04
Warfield PR, Makker PN, Raz A, Ochieng J. Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin-3. Invasion Metastasis. 1997;17:101–12.
pubmed: 9561029